Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

19.8%

16 terminated/withdrawn out of 81 trials

Success Rate

79.7%

-6.8% vs industry average

Late-Stage Pipeline

46%

37 trials in Phase 3/4

Results Transparency

76%

48 of 63 completed trials have results

Key Signals

48 with results13 terminated

Enrollment Performance

Analytics

Phase 3

33(42.3%)

Phase 1

27(34.6%)

Phase 2

13(16.7%)

Phase 4

4(5.1%)

N/A

1(1.3%)

78Total

Phase 3(33)

Phase 1(27)

Phase 2(13)

Phase 4(4)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (81)

Showing 20 of 81 trials

NCT07543276Phase 1Completed

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

Role: lead

NCT06285214Phase 1Completed

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Role: collaborator

NCT06545916Phase 2Active Not Recruiting

Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Role: collaborator

NCT06545929Phase 2Completed

Study of Sunobinop on Craving in Alcohol Use Disorder

Role: collaborator

NCT06719986Phase 1Completed

Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg

Role: lead

NCT06024642Phase 1Completed

Study of V117957 in Overactive Bladder Syndrome

Role: collaborator

NCT03299556Completed

Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System

Role: lead

NCT04035200Phase 2Completed

Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation

Role: collaborator

NCT04987762Phase 4Terminated

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

Role: lead

NCT04507204Phase 4Terminated

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Role: lead

NCT05808881Phase 4Withdrawn

Clinical Outcomes From Nalmefene

Role: lead

NCT02970500Phase 2Terminated

Effect of Methylphenidate on Cancer-related Cognitive Impairment

Role: collaborator

NCT02796625Not ApplicableCompleted

Alpha as a Predictive Biomarker

Role: collaborator

NCT03001557Phase 2Completed

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

Role: collaborator

NCT03158025Phase 1Completed

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Role: collaborator

NCT01192295Phase 3Completed

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Role: lead

NCT03440424Phase 1Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Role: collaborator

NCT03443063Phase 1Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Role: collaborator

NCT01452529Phase 3Completed

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

Role: lead

NCT01400139Phase 3Completed

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

Role: lead